Hyloris Pharmaceuticals (XBRU:HYL) Long-Term Capital Lease Obligation : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Long-Term Capital Lease Obligation?

Hyloris Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil.

Hyloris Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (€0.75 Mil) to Jun. 2023 (€0.00 Mil) but then stayed the same from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Hyloris Pharmaceuticals's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€0.11 Mil) to Dec. 2022 (€0.75 Mil) but then declined from Dec. 2022 (€0.75 Mil) to Dec. 2023 (€0.00 Mil).

Hyloris Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Hyloris Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Long-Term Capital Lease Obligation Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.02

0.11

0.75

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial							0.11	0.04	0.75	-	-

Hyloris Pharmaceuticals (XBRU:HYL) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Hyloris Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.